ClinicalTrials.gov record
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma
ClinicalTrials.gov ID: NCT00720941
Public ClinicalTrials.gov record NCT00720941. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Study VEG108844, A Study of Pazopanib Versus Sunitinib in the Treatment of Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a randomized, open-label, parallel group Phase III non inferiority study to evaluate the efficacy and safety of pazopanib compared with sunitinib in subjects with advanced renal cell carcinoma (RCC) who had not received prior systemic therapy for advanced or metastatic RCC.
Study identification
- NCT ID
- NCT00720941
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,110 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 13, 2008
- Primary completion
- May 20, 2012
- Completion
- Mar 23, 2021
- Last update posted
- Mar 29, 2025
2008 – 2021
United States locations
- U.S. sites
- 96
- U.S. states
- 34
- U.S. cities
- 85
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Huntsville | Alabama | 35805 | — |
| Novartis Investigative Site | Tucson | Arizona | 85710 | — |
| Novartis Investigative Site | Little Rock | Arkansas | 72205 | — |
| Novartis Investigative Site | Beverly Hills | California | 90211 | — |
| Novartis Investigative Site | Escondido | California | 92025 | — |
| Novartis Investigative Site | Fresno | California | 93720 | — |
| Novartis Investigative Site | Greenbrae | California | 94904-2007 | — |
| Novartis Investigative Site | Hayward | California | 94545 | — |
| Novartis Investigative Site | La Jolla | California | 92037 | — |
| Novartis Investigative Site | Los Angeles | California | 90095 | — |
| Novartis Investigative Site | Montebello | California | 90640 | — |
| Novartis Investigative Site | Oakland | California | 94611 | — |
| Novartis Investigative Site | Orange | California | 92868 | — |
| Novartis Investigative Site | Roseville | California | 95661 | — |
| Novartis Investigative Site | Sacramento | California | 95817 | — |
| Novartis Investigative Site | Sacramento | California | 95825 | — |
| Novartis Investigative Site | San Bernardino | California | 92404 | — |
| Novartis Investigative Site | San Francisco | California | 94115 | — |
| Novartis Investigative Site | San Jose | California | 95119-1110 | — |
| Novartis Investigative Site | Santa Clara | California | 95051 | — |
| Novartis Investigative Site | South San Francisco | California | 94080 | — |
| Novartis Investigative Site | Vallejo | California | 94589 | — |
| Novartis Investigative Site | Walnut Creek | California | 94596 | — |
| Novartis Investigative Site | Denver | Colorado | 80218 | — |
| Novartis Investigative Site | Southington | Connecticut | 06489 | — |
| Novartis Investigative Site | Trumbull | Connecticut | 06611 | — |
| Novartis Investigative Site | Washington D.C. | District of Columbia | 20007 | — |
| Novartis Investigative Site | Fort Myers | Florida | 33916 | — |
| Novartis Investigative Site | Miami | Florida | 33136 | — |
| Novartis Investigative Site | Orlando | Florida | 32806 | — |
| Novartis Investigative Site | Atlanta | Georgia | 30318 | — |
| Novartis Investigative Site | Chicago | Illinois | 60612 | — |
| Novartis Investigative Site | Elk Grove Village | Illinois | 60007 | — |
| Novartis Investigative Site | Maywood | Illinois | 60153 | — |
| Novartis Investigative Site | Peoria | Illinois | 61615-7822 | — |
| Novartis Investigative Site | Carmel | Indiana | 46032 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46202 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46237 | — |
| Novartis Investigative Site | Cedar Rapids | Iowa | 52403 | — |
| Novartis Investigative Site | Louisville | Kentucky | 40202 | — |
| Novartis Investigative Site | Paducah | Kentucky | 42003 | — |
| Novartis Investigative Site | Annapolis | Maryland | 21401 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02114 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02115 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02215 | — |
| Novartis Investigative Site | Worcester | Massachusetts | 01608 | — |
| Novartis Investigative Site | Detroit | Michigan | 48201 | — |
| Novartis Investigative Site | Duluth | Minnesota | 55805 | — |
| Novartis Investigative Site | Minneapolis | Minnesota | 55455 | — |
| Novartis Investigative Site | Tupelo | Mississippi | 38801 | — |
| Novartis Investigative Site | Kansas City | Missouri | 64118 | — |
| Novartis Investigative Site | Kansas City | Missouri | 64131 | — |
| Novartis Investigative Site | Lincoln | Nebraska | 68510 | — |
| Novartis Investigative Site | Las Vegas | Nevada | 89135 | — |
| Novartis Investigative Site | Las Vegas | Nevada | 89169 | — |
| Novartis Investigative Site | Lebanon | New Hampshire | 03756 | — |
| Novartis Investigative Site | Hackensack | New Jersey | 07601 | — |
| Novartis Investigative Site | Buffalo | New York | 14215 | — |
| Novartis Investigative Site | New York | New York | 10032 | — |
| Novartis Investigative Site | New York | New York | 10065 | — |
| Novartis Investigative Site | Hickory | North Carolina | 28602 | — |
| Novartis Investigative Site | Raleigh | North Carolina | 27607 | — |
| Novartis Investigative Site | Cincinnati | Ohio | 45242 | — |
| Novartis Investigative Site | Cleveland | Ohio | 44106 | — |
| Novartis Investigative Site | Columbus | Ohio | 43210 | — |
| Novartis Investigative Site | Columbus | Ohio | 43219 | — |
| Novartis Investigative Site | Dayton | Ohio | 45429 | — |
| Novartis Investigative Site | Oklahoma City | Oklahoma | 73120 | — |
| Novartis Investigative Site | Tulsa | Oklahoma | 74136 | — |
| Novartis Investigative Site | Eugene | Oregon | 97401 | — |
| Novartis Investigative Site | Portland | Oregon | 97213 | — |
| Novartis Investigative Site | Philadelphia | Pennsylvania | 19102 | — |
| Novartis Investigative Site | Philadelphia | Pennsylvania | 19111 | — |
| Novartis Investigative Site | Charleston | South Carolina | 29403 | — |
| Novartis Investigative Site | Charleston | South Carolina | 29425 | — |
| Novartis Investigative Site | Greenville | South Carolina | 29605 | — |
| Novartis Investigative Site | Mt. Pleasant | South Carolina | 29464 | — |
| Novartis Investigative Site | Chattanooga | Tennessee | 37404 | — |
| Novartis Investigative Site | Nashville | Tennessee | 37203 | — |
| Novartis Investigative Site | Arlington | Texas | 76012 | — |
| Novartis Investigative Site | Bedford | Texas | 76022 | — |
| Novartis Investigative Site | Corpus Christi | Texas | 78463-3069 | — |
| Novartis Investigative Site | Dallas | Texas | 75246 | — |
| Novartis Investigative Site | Fort Worth | Texas | 76104 | — |
| Novartis Investigative Site | Lubbock | Texas | 79410 | — |
| Novartis Investigative Site | Round Rock | Texas | 78681 | — |
| Novartis Investigative Site | San Antonio | Texas | 78229 | — |
| Novartis Investigative Site | Tyler | Texas | 75702 | — |
| Novartis Investigative Site | Webster | Texas | 77598-4420 | — |
| Novartis Investigative Site | Wichita Falls | Texas | 76310 | — |
| Novartis Investigative Site | Charlottesville | Virginia | 22903 | — |
| Novartis Investigative Site | Hampton | Virginia | 23666 | — |
| Novartis Investigative Site | Richmond | Virginia | 23230 | — |
| Novartis Investigative Site | Salem | Virginia | 24153 | — |
| Novartis Investigative Site | Seattle | Washington | 98101 | — |
| Novartis Investigative Site | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 131 non-U.S. sites.
Recently updated Carcinoma, Renal Cell trials
Other public records listing Carcinoma, Renal Cell. Sorted by last update posted; newest first. Not a recommendation.
- NCT04626479: Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) Active, not recruiting
- NCT07489495: A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) Recruiting
- NCT07405164: Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) Recruiting
- NCT05239728: A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) Active, not recruiting
- NCT04195750: A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) Active, not recruiting
- NCT04736706: A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00720941, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 29, 2025 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00720941 live on ClinicalTrials.gov.